Evidence Level
Vitamin K2 (MK-7) is emerging as a significant factor in bone and cardiovascular health. A 3-year randomized controlled trial by Knapen et al. (2013) involving 244 postmenopausal women demonstrated that MK-7 supplementation at 180 mcg/day effectively reduced bone mineral density decline at the lumbar spine and femoral neck, highlighting its role in preserving bone health. Additionally, a randomized crossover study by Schurgers et al. (2007) with 23 participants found that MK-7 has a longer half-life compared to vitamin K1, leading to more efficient osteocalcin carboxylation, which is crucial for bone formation.
In the context of cardiovascular health, the Rotterdam Study by Geleijnse et al. (2004), involving 4,807 participants, revealed that higher dietary intake of menaquinone was associated with a reduced risk of coronary heart disease and aortic calcification. This study underscored the importance of MK-7 over K1 in cardiovascular protection. Mechanistically, MK-7 activates osteocalcin, promoting bone formation, and MGP (matrix Gla protein), which inhibits vascular calcification, providing a dual benefit for both skeletal and cardiovascular systems.
Despite these findings, there remains a need for larger-scale randomized controlled trials to further validate the cardiovascular benefits of MK-7 and to explore its potential interactions with anticoagulant therapies at higher doses.